Titlebook: Macromolecular Anticancer Therapeutics; L. Harivardhan Reddy,Patrick Couvreur Book 2010 Springer-Verlag New York 2010 cancer.cancer therap

只看該作者 · 發(fā)表于 2025-3-26 23:19:10

Immunoconjugate Anticancer Therapeuticse “dock-and-lock” (DNL) technology enables the facile assembly of multifunctional structures of defined composition, combining the targeting and the therapeutic moieties site specifically. Recent advances in the use of different classes of immunoconjugates are described.

只看該作者 · 發(fā)表于 2025-3-27 01:48:18

只看該作者 · 發(fā)表于 2025-3-27 06:50:50

只看該作者 · 發(fā)表于 2025-3-27 12:32:44

Monoclonal Antibody Therapy for Hematologic Malignanciesmphomas in the Western world, is rituximab combined with chemotherapy. Second-generation anti-CD20 monoclonal antibodies are currently being studied in phase II and III trials. Radioimmunotherapy with anti-CD20 antibodies has also been approved by the FDA for the second-line treatment of follicular

只看該作者 · 發(fā)表于 2025-3-27 14:00:28

只看該作者 · 發(fā)表于 2025-3-27 18:22:45

只看該作者 · 發(fā)表于 2025-3-28 00:57:34

只看該作者 · 發(fā)表于 2025-3-28 03:13:30

只看該作者 · 發(fā)表于 2025-3-28 08:32:28

只看該作者 · 發(fā)表于 2025-3-28 10:55:12

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 05:13
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved